Nk receptors: Tools for a polyvalent cell family

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Sivori, Simona ^a   Olive, Daniel ^b,c,d,e   López Botet, Miguel ^f   Vitale, Massimo ^g  

^a UNIVERSITY OF GENOA   (Italy)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CNRS   (France)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti tumor immunity; Anti viral immune responses; Autoimmune diseases; Decidual; ILC; Innate immunity; KIR; NCR; NK cell

Indexed keywords

CELL SURFACE RECEPTOR; HLA A ANTIGEN; INTERLEUKIN 22; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

AUTOIMMUNITY; CELL DAMAGE; CRYSTAL STRUCTURE; DECIDUA; EDITORIAL; FIRST TRIMESTER PREGNANCY; HEPATITIS C VIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; PROTEIN EXPRESSION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; STRESS; VIRUS INFECTION;

EID: 84919762238     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00617     Document Type: Editorial

References (23)

1. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 5:201-14. doi: 10.1038/nri1570
2. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687
3. Sivori S, Carlomagno S, Pesce S, Moretta A, Vitale M, Marcenaro E. TLR/NCR/KIR: which one to use and when? Front Immunol (2014) 5:105. doi:10.3389/fimmu.2014.00105
4. Li Y, Mariuzza RA. Structural basis for recognition of cellular and viral ligands by NK cell receptors. Front Immunol (2014) 5:123. doi:10.3389/fimmu.2014.00123
5. Cassidy SA, Cheent KS, Khakoo SI. Effects of Peptide on NK cell-mediated MHC I recognition. Front Immunol (2014) 5:133. doi:10.3389/fimmu.2014.00133
6. Zambello R, Teramo A, Barila G, Gattazzo C, Semenzato G. Activating KIRs in chronic lymphoproliferative disorder of NK cells: protection from viruses and disease induction? Front Immunol (2014) 5:72. doi:10.3389/fimmu.2014.00072
7. Ivarsson MA, Michaelsson J, Fauriat C. Activating killer cell Ig-like receptors in health and disease. Front Immunol (2014) 5:184. doi:10.3389/fimmu.2014.00184
8. Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol (2014) 4:508. doi:10.3389/fimmu.2013.00508
9. Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular bases for the regulation of NKG2D ligands in cancer. Front Immunol (2014) 5:106. doi:10.3389/fimmu.2014.00106
10. Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, et al. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol (2014) 5:56. doi:10.3389/fimmu.2014.00056
11. Baier C, Fino A, Sanchez C, Farnault L, Rihet P, Kahn-Perles B, et al. Natural killer cells modulation in hematological malignancies. Front Immunol (2013) 4:459. doi:10.3389/fimmu.2013.00459
12. Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, et al. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol (2014) 5:95. doi:10.3389/fimmu.2014.00095
13. Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol (2014) 5:122. doi:10.3389/fimmu.2014.00122
14. Lugli E, Marcenaro E, Mavilio D. NK cell subset redistribution during the course of viral infections. Front Immunol (2014) 5:390. doi:10.3389/fimmu.2014.00390
15. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: the paradigm of HIV-1 and HCV. Front Immunol (2014) 5:305. doi:10.3389/fimmu.2014.00305
16. Le Bouteiller P. Human decidual NK cells: unique and tightly regulated effector functions in healthy and pathogen-infected pregnancies. Front Immunol (2013) 4:404. doi:10.3389/fimmu.2013.00404
17. Cella M, Miller H, Song C. Beyond NK cells: the expanding universe of innate lymphoid cells. Front Immunol (2014) 5:282. doi:10.3389/fimmu.2014.00282
18. Killig M, Glatzer T, Romagnani C. Recognition strategies of group 3 innate lymphoid cells. Front Immunol (2014) 5:142. doi:10.3389/fimmu.2014.00142
19. Reiners KS, Dassler J, Coch C, Pogge Von Strandmann E. Role of exosomes released by dendritic cells and/or by tumor targets: regulation of NK cell plasticity. Front Immunol (2014) 5:91. doi:10.3389/fimmu.2014.00091
20. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol (2014) 5:159. doi:10.3389/fimmu.2014.00159
21. Poggi A, Zocchi MR. NK cell autoreactivity and autoimmune diseases. Front Immunol (2014) 5:27. doi:10.3389/fimmu.2014.00027
22. Enk J, Mandelboim O. The role of natural cytotoxicity receptors in various pathologies: emphasis on type I diabetes. Front Immunol (2014) 5:4. doi:10.3389/fimmu.2014.00004
23. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 11:237-44. doi:10.1016/0167-5699(90)90097-S